Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Formulation 1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Formulation 1 | EXPERIMENTAL | - |
| Formulation 2 | EXPERIMENTAL | - |
| Formulation 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Formulation 1 | DRUG | 150-mg immediate release tablet (single dose) |
| Formulation 2 | DRUG | 150-mg modified release capsule, short duration (single dose) |
| Formulation 3 | DRUG | 150-mg modified release capsule, long duration (single dose) |
Inclusion Criteria: * Healthy male and/or female (non-childbearing potential) subjects between the ages of 21 and 55 years, inclusive. * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs). * An informed consent document signed and dated by the subject. Exclusion...
Formulation 1 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial evaluating its pharmacokinetics. The drug is not approved for any indication and remains under investigation.
Formulation 1 is being developed by Pfizer, Inc. (NYSE: PFE). The company is conducting clinical research on this investigational small molecule, which is currently in Phase 1 development.
Formulation 1 is in Phase 1 clinical development. It is an investigational drug, not yet approved, and is being studied in healthy volunteers to assess its pharmacokinetics. One Phase 1 trial has been completed.
Formulation 1 has one completed clinical trial, NCT01351129, titled "Single Dose Study To Compare Pharmacokinietics Of 3 Different Formulations Of PF-04991532 In Healthy Volunteers." This Phase 1 study enrolled 12 participants in Singapore and was a controlled, randomized trial.
Yes, Formulation 1 is a formulation of PF-04991532. The completed clinical trial NCT01351129 compared the pharmacokinetics of three different formulations of PF-04991532, including Formulation 1, in healthy volunteers.